乳腺癌新辅助治疗后的外科处理

doi:10.16139/j.1007-9610.2019.05.004

摘要/Abstract

中图分类号:

R737.9

陈祥锦, 朱有志. 乳腺癌新辅助治疗后的外科处理[J]. 外科理论与实践, 2019, 24(05): 388-390.

[1] Rubens RD, Sexton S, Tong D, et al.Combined chemotherapy and radiotherapy for locally advanced breast cancer[J]. Eur J Cancer,1980,16(3):351-356.
[2] Masuda N, Lee SJ, Ohtani S, et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med,2017,376(22):2147-2159.
[3] von Minckwitz GG, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med,2019,380(7):617-628.
[4] Wolmark N, Wang J, Mamounas E, et al.Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr,2001,30:96-102.
[5] Bear HD, Anderson S, Smith RE, et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol,2004,24(13):2019-2027.
[6] Cortazar P, Zhang L, Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet Oncol,2014,384(9938):164-172.
[7] Minckwitz GV, Kümmel S, Vogel P, et al.Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial[J]. J Natl Cancer Inst,2008,100(8):542-551.
[8] Keklikoglou I, Cianciaruso C, Güç E, et al.Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models[J]. Nat Cell Biol,2019,21(2):190-202.
[9] Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism[J]. Sci Transl Med,2017,9(397).pii: eaan0026.
[10] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol,2018,19(1):27-39.
[11] El-Didi MH, Moneer MM, Khaled HM, et al.Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management[J]. Surg Today,2000,30(3):249-254.
[12] Straver ME, Loo CE. Rutgers EJ, et al.MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy[J]. Ann Surg,2010,251(4):701-707.
[13] Marinovich ML, Houssami N, Macaskill P, et al.Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy[J]. J Natl Cancer Inst,2013,105(5):321-333.
[14] Mamounas EP, Anderson SJ, Dignam JJ, et al.Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27[J]. J Clin Oncol,2012,30(32):3960-3966.
[15] Dash N, Chafin SH, Johnson RR, et al.Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer[J]. Am J Roentgenol,1999,173(4):911-917.
[16] Oh JL, Nguyen G, Whitman GJ, et al.Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy[J]. Cancer,2007,110(11):2420-2427.
[17] Pilewskie M, Morrow M.Axillary nodal management following neoadjuvant chemotherapy[J]. JAMA Oncology,2017,3(4):549-555.
[18] Kuehn T, Bauerfeind I, Fehm T, et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol,2013,14(7):609-618.
[19] Boughey JC, Suman VJ, Mittendorf EA, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA,2013,310(14):1455-1461.

乳腺癌新辅助治疗后的外科处理

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张小丽　李赞　宋达疆　王业成　海涛. 带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-.
[2]	宋达疆　李赞　章一新. 带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[3]	许梓枫, 宗雅萍, 陆爱国. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(3): 266-270.
[4]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲. 硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[5]	廖晓明　蒋奕　唐玮　杨华伟　姬逸男　韦莉颖. 薄层血管化腹股沟淋巴结皮瓣移植联合反向淋巴显影在继发性上肢淋巴水肿手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(1): 8-.
[6]	宋景涌汤鹏钟晓捷刘侠孙洋亢玉王遥佳陈安玥陈怡安吉训通周艳虹蒋曼妃修骋穆籣. 吻合口通畅性量化分析应用于乳腺癌腋窝淋巴结清扫术同期预防性淋巴管静脉吻合1例[J]. 组织工程与重建外科杂志, 2022, 18(1): 34-.
[7]	陈小松, 沈坤炜, 李宏为. 早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386.
[8]	吴佳毅, 陆裕杰, 何金光, 沈坤炜, 徐华. 乳腺癌术后植入物乳房重建技术[J]. 外科理论与实践, 2022, 27(05): 387-391.
[9]	陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.
[10]	谢妍妍, 吕青, 杜正贵. 乳腺腔镜和机器人手术的现状及未来之路——华西医院经验分享[J]. 外科理论与实践, 2022, 27(05): 396-402.
[11]	周文斌, 唐新宇, 王水. 局部微波消融技术在乳腺癌治疗中的应用[J]. 外科理论与实践, 2022, 27(05): 403-405.
[12]	曹璐, 郑思悦, 陈佳艺. 早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.
[13]	黄蔚, 李恒宇, 丁晓毅. 晚期乳腺癌介入诊疗的价值及应用[J]. 外科理论与实践, 2022, 27(05): 411-415.
[14]	舒兰, 陈小松. ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022, 27(05): 416-420.
[15]	杨崔燕, 王豪雨, 陈小松, 沈坤炜. 抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428.